Medicus Pharma Ltd (MDCX)

Medicus Pharma Ltd. stock has experienced volatility driven by clinical trial results and regulatory news, with a decline of approximately 86.04% over the last six months and 92.33% over the past year. In May 2026, Medicus Pharma announced positive dose-response results from a pre-specified expanded Phase 2 SKNJCT-003 data analysis. In April 2026, the CEO met with lawmakers, submitted an Orphan Drug Designation Application for SkinJect in Gorlin Syndrome, presented new Teverelix data, and submitted an optimized Phase 2 study protocol for Teverelix in acute urinary retention. In March 2026, the company reported full-year 2025 financial results and highlighted the completed 90-patient Phase 2 SkinJect study, but the stock plummeted due to skepticism around regulatory pathways and financial sustainability. In December 2025, Carolyn Bonner was appointed as CFO. Medicus Pharma received a Nasdaq non-compliance notice and is pursuing a share consolidation to regain compliance.

Information regarding specific demand seasonality for Medicus Pharma Ltd.'s products and services is limited. Demand for its products, once commercialized, would likely be driven by disease prevalence, diagnosis rates, and treatment cycles rather than typical seasonal consumer patterns. Direct market demand seasonality is not yet a primary factor.

Medicus Pharma Ltd. is a biotechnology and life sciences company focused on accelerating the clinical development of therapeutic assets. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - General and Biotechnology industries. Medicus Pharma advances drug candidates through Phase 2 studies, then pursues licensing or strategic partnerships. Its major products include SkinJect, a microneedle patch for basal cell carcinoma and Gorlin Syndrome, and Teverelix, a GnRH antagonist for advanced prostate cancer.

Medicus Pharma Ltd. is engaged in multiple countries across three continents. Clinical operations for SkinJect are active in the United States, with approvals for expansion into the United Kingdom, and a Phase 2 study in the United Arab Emirates. The company was incorporated in Ontario, Canada, and its shares trade on The Nasdaq Capital Market. Its headquarters are in Conshohocken, Pennsylvania, United States.

Medicus Pharma Ltd.'s brand reputation has been influenced by clinical development progress and financial standing. Positive clinical trial results and regulatory milestones have been favorable, while stock price declines and Nasdaq non-compliance have presented challenges. Market skepticism regarding regulatory pathways, financial sustainability, and potential future dilution have impacted its brand perception among investors.

Medicus Pharma Ltd. has 23 institutional owners and shareholders holding a total of 4,068,729 shares. Major institutional shareholders include Armistice Capital, Llc, Interchange Capital Partners, LLC, and Private Advisor Group, LLC. VC/PE Firms hold 7.21% of shares, individual insiders hold 9.41%, institutions hold 12.4%, and the general public holds 71%.